Special drug use surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate cancer"
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Takeda Pharma
- 29 Nov 2017 Status changed from active, no longer recruiting to completed.
- 01 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2016 New trial record